Healthcare & Life Sciences

Ascendo Biotechnology, Inc

series-a

Stage

About

Ascendo Biotechnology is a Phase 1 clinical-stage company developing first-in-class innate immune-checkpoint therapies for cancer and autoimmune diseases, with its lead candidate ASD141 being an anti-CD11b antibody aimed at activating innate immunity in tumors resistant to PD-1/PD-L1 therapy.

Explore Ascendo Biotechnology, Inc's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.